Companies Lineage Cell Therapeutics
Lineage Cell Therapeutics (LCTX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Lineage Cell Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,905,130FY2023
- $2,534,450FY2024
- $2,111,170FY2025
CEO total pay was $2,111,170 in fiscal 2025, down from $2,534,450 in fiscal 2024.
FY2025: salary $691,800 · bonus $0 · stock awards $0 · option awards $882,970
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Brian Culley | $691,800 | $0 | $0 | $882,970 | $518,900 | $0 | $17,500 | $2,111,170 |
| Chief Executive Officer | ||||||||
| Jill Howe | 467,000 | 0 | 0 | 287,925 | 233,500 | 0 | 17,500 | 1,005,925 |
| Chief Financial Officer | ||||||||
| George Samuel III | 448,500 | 0 | 0 | 287,925 | 224,300 | 0 | 17,500 | 978,225 |
| General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Brian Culley | $2,111,170 | $2,534,450 | $2,905,130 | ↓ −423,280 |
| Jill Howe | 1,005,925 | 1,114,100 | 738,855 | ↓ −108,175 |
| George Samuel III | 978,225 | 1,113,600 | 1,210,813 | ↓ −135,375 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee aims to be competitive in executive hiring and retention by targeting market pay percentiles based on peer group data.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Anderson |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brian Culley | OPTION | 2025-03-10 | — | — | 2,300,000 | — | $882,970 |
| Jill Howe | OPTION | 2025-03-10 | — | — | 750,000 | — | 287,925 |
| George Samuel III | OPTION | 2025-03-10 | — | — | 750,000 | — | 287,925 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Brian Culley | $0 | $0 | $882,970 | 0.0% |
| Jill Howe | 0 | 0 | 287,925 | 0.0% |
| George Samuel III | 0 | 0 | 287,925 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| George Samuel III | RSU | 28,646 | — | $10,147 |
| George Samuel III | Option | 40,625 | 1.4 | — |
| Jill Howe | Option | 46,875 | 1.46 | — |
| Brian Culley | Option | 78,125 | 1.4 | — |
| Brian Culley | RSU | 147,320 | — | 52,186 |
| George Samuel III | Option | 203,125 | 1.46 | — |
| Jill Howe | Option | 229,167 | 1.36 | — |
| George Samuel III | Option | 365,625 | 1.13 | — |
| Jill Howe | Option | 365,625 | 1.13 | — |
| Brian Culley | Option | 593,750 | 1.46 | — |
| George Samuel III | Option | 750,000 | 0.53 | — |
| Jill Howe | Option | 750,000 | 0.53 | — |
| Brian Culley | Option | 1,068,750 | 1.13 | — |
| Brian Culley | Option | 2,300,000 | 0.53 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael H. MulroyIndependent · Audit | $115,000 | $0 | $45,990 | — | $0 | $160,990 |
| Deborah AndrewsIndependent · Audit (Chair) · Compensation | 77,500 | 0 | 45,990 | — | 0 | 123,490 |
| Angus C. RussellIndependent · Audit | 75,000 | 0 | 45,990 | — | 0 | 120,990 |
| Neal C. BradsherIndependent · Nominating & Corporate Governance (Chair) · Financial Strategy | 72,500 | 0 | 45,990 | — | 0 | 118,490 |
| Dipti AminIndependent · Compensation | 57,500 | 0 | 45,990 | — | 0 | 103,490 |
| Anula JayasuriyaIndependent · Nominating CorporateGovernance | 57,500 | 0 | 45,990 | — | 0 | 103,490 |
| Brian M. CulleyEmployee director · Financial Strategy (Chair) | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 15,000 |
| Stock ownership guideline | Under these guidelines, our directors are required to hold at least 10,000 common shares three years following the date of their election to our Board. |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $455,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $455,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Lineage Cell Therapeutics as a peer
Companies that benchmark against LCTX
6 companies name LCTX as a compensation peer
- Adverum Biotechnologies, Inc.ADVMFY2024
- Cartesian Therapeutics, Inc.RNACFY2025
- Definium Therapeutics, Inc.DFTXFY2025
- DiaMedica Therapeutics Inc.DMACFY2025
- Opus Genetics, Inc.IRDFY2025
- Stoke Therapeutics, Inc.STOKFY2025
Each company listed discloses LCTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named LCTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies Lineage Cell Therapeutics names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Vor Biopharma Inc. | 2025 | Jean-Paul Kress | $344,615 | $0 | $64,013,465 | $251,425 | $65,027,569 |
| 2 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 3 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 4 | Cartesian Therapeutics, Inc. | 2025 | Carsten Brunn | 674,000 | 973,475 | 2,314,320 | 363,960 | 4,329,868 |
| 5 | Adverum Biotechnologies, Inc. | 2024 | Laurent Fischer | 691,795 | 171,363 | 2,839,252 | 415,080 | 4,131,290 |
| 6 | Capricor Therapeutics, Inc | 2025 | Linda Marbán | 300,000 | 0 | 2,940,920 | 0 | 3,521,565 |
| 7 | Nkarta, Inc. | 2025 | Paul Hastings | 674,384 | 236,250 | 1,711,957 | 344,947 | 2,978,038 |
| 8 | Sana Biotechnology, Inc. | 2025 | Steven Harr | 696,140 | 425,001 | 1,327,500 | 450,369 | 2,903,010 |
| 9 | Verastem, Inc. | 2025 | Daniel Paterson | 674,000 | 1,161,661 | 0 | 489,324 | 2,349,975 |
| 10 | Fate Therapeutics, Inc. | 2025 | Bahram Valamehr | 600,000 | 0 | 1,283,868 | 360,000 | 2,248,568 |
| 11 | Lineage Cell Therapeutics | 2025 | Brian Culley | 691,800 | 0 | 882,970 | 518,900 | 2,111,170 |
| 12 | Kyverna Therapeutics Inc | 2025 | Warner Biddle | 625,000 | 0 | 543,804 | 468,750 | 1,814,980 |
| 13 | Agenus Inc. | 2025 | Garo Armen | 715,260 | 0 | 141,000 | 0 | 1,350,325 |
| 14 | Chimerix Inc | 2023 | Mike Andriole | 528,473 | 93,135 | 399,282 | 280,500 | 1,312,421 |
| 15 | Century Therapeutics, Inc. | 2025 | Gregory Russotti | 559,650 | 71,120 | 51,240 | 226,658 | 912,320 |
| — | BioAtla, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Lineage Cell Therapeutics | not disclosed | not disclosed | not disclosed | Anderson |
| Adverum Biotechnologies, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Agenus Inc. | 125% | Options 100 | not disclosed | Aon Radford |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| BioAtla, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Capricor Therapeutics, Inc | 25% to 90% of base salary% | not disclosed | not disclosed | Pay Governance LLC |
| Cartesian Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Compensia |
| Century Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Chimerix Inc | 85% | Option 86 · RSU 14 | not disclosed | Aon |
| Fate Therapeutics, Inc. | 100% | Options 100 | No | Aon's Human Capital Solutions practice (Radford) |
| Kyverna Therapeutics Inc | not disclosed | Option 100 | not disclosed | Aon plc |
| Nkarta, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Sana Biotechnology, Inc. | 107.5% | not disclosed | not disclosed | Aon plc (Human Capital Solutions practice) |
| Verastem, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Vor Biopharma Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 88,328,168 | 2,600,932 | 655,685 | 97.14% | Passed |
| 2025 | 2025-06-26 | 96,071,162 | 3,804,451 | 611,814 | 96.19% | Passed |
| 2024 | 2024-06-11 | 87,812,598 | 3,704,495 | 746,596 | 95.95% | Passed |
| 2023 | 2023-09-06 | 70,271,698 | 4,542,895 | 561,807 | 93.23% | Passed |
| 2022 | 2022-06-16 | 70,879,474 | 1,813,619 | 1,802,356 | 97.51% | Passed |
| 2021 | 2021-09-13 | 70,898,473 | 3,204,251 | 616,948 | 95.68% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 97.14%a |
| 2025 | 2025-06-26 | 96.19%b |
| 2024 | 2024-06-11 | 95.95%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (36 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Brian Culley. DEF 14A, filed 2026-04-29. Section “Executive Compensation” · page 20. As printed: 2,111,170. View filing ↗
- Section 01, Jill Howe. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 1,005,925. View filing ↗
- Section 01, George Samuel III. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 978,225. View filing ↗
- Section 03, Brian Culley OPTION. DEF 14A, filed 2026-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jill Howe OPTION. DEF 14A, filed 2026-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, George Samuel III OPTION. DEF 14A, filed 2026-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Michael H. Mulroy. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 160,990. View filing ↗
- Section 08, Deborah Andrews. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 123,490. View filing ↗
- Section 08, Angus C. Russell. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 120,990. View filing ↗
- Section 08, Neal C. Bradsher. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 118,490. View filing ↗
- Section 08, Dipti Amin. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 103,490. View filing ↗
- Section 08, Anula Jayasuriya. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 103,490. View filing ↗
- Section 08, Brian M. Culley. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 97.14% (votes for as printed: 88,328,168). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-07-02. Item 5.07 · say-on-pay result. As reported: 96.19% (votes for as printed: 96,071,162). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-13. Item 5.07 · say-on-pay result. As reported: 95.95% (votes for as printed: 87,812,598). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 455,000 + equity 0 + all other 0 = 455,000, summed across the director compensation table rows.
- Vor Biopharma Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Vor Biopharma Inc.'s own proxy. As printed: 65,027,569. View filing ↗
- Allogene Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. View filing ↗
- AnaptysBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. View filing ↗
- Cartesian Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cartesian Therapeutics, Inc.'s own proxy. As printed: 4,329,868. View filing ↗
- Adverum Biotechnologies, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Adverum Biotechnologies, Inc.'s own proxy. As printed: 4,131,290. View filing ↗
- Capricor Therapeutics, Inc, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Capricor Therapeutics, Inc's own proxy. As printed: 3,521,565. View filing ↗
- Nkarta, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Nkarta, Inc.'s own proxy. As printed: 2,978,038. View filing ↗
- Sana Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sana Biotechnology, Inc.'s own proxy. As printed: 2,903,010. View filing ↗
- Verastem, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Verastem, Inc.'s own proxy. As printed: 2,349,975. View filing ↗
- Fate Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Fate Therapeutics, Inc.'s own proxy. As printed: 2,248,568. View filing ↗
- Lineage Cell Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Lineage Cell Therapeutics's own proxy. As printed: 2,111,170. View filing ↗
- Kyverna Therapeutics Inc, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Kyverna Therapeutics Inc's own proxy. As printed: 1,814,980. View filing ↗
- Agenus Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Agenus Inc.'s own proxy. As printed: 1,350,325. View filing ↗
- Chimerix Inc, Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Chimerix Inc's own proxy. As printed: 1,312,421. View filing ↗
- Century Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Century Therapeutics, Inc.'s own proxy. As printed: 912,320. View filing ↗
- Section 10a, Adverum Biotechnologies, Inc. reciprocity. DEF 14A. Adverum Biotechnologies, Inc. names Lineage Cell Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Cartesian Therapeutics, Inc. reciprocity. DEF 14A. Cartesian Therapeutics, Inc. names Lineage Cell Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗